ABBV vs JPM: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and JPMorgan Chase & Co. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-15.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
JPMorgan Chase & Co. · Financial Services
$350.13
+26.9% upside to fair value
Med Conviction
Grade A-
High Quality
QuantHub Verdict
JPM has more upside to fair value
(+26.9%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
JPM |
| Current Price |
$261.70 |
$350.13 |
| Fair Value Estimate |
$259.04 |
$444.48 |
| Upside to Fair Value |
-1.0%
|
+26.9%
|
| Market Cap |
$462.4B |
$938.2B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
20.0x
|
| Price / Sales |
7.2x
|
3.1x
|
| Price / FCF |
23.6x
|
—
|
| Revenue Growth YoY |
+10.2%
|
+17.9%
|
| Gross Margin |
71.5%
|
62.6%
|
| Operating Margin |
29.3%
|
28.2%
|
| Return on Equity |
-136.5%
|
17.8%
|
| Dividend Yield |
2.61% |
1.71% |
| FCF Yield |
4.25%
|
—
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
JPMorgan Chase is a diversified global bank spanning consumer banking, cards, payments, commercial banking, investment banking, markets, treasury services, and asset and wealth management, with an unusually high-quality franchise supported by funding scale, distribution, leading market positions and cross-selling across 86.6 million U.S. consumers and more than 90% of Fortune 500 companies. Busin…
Accumulation Zones
| Metric |
ABBV |
JPM |
| Zone Low |
$194.28 |
$333.36 |
| Zone High |
$220.18 |
$377.81 |
| In Buy Zone? |
No
|
Yes
|